EXEL Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 28.74% compared to Exelixis's net margin of 19.72%. Exelixis's return on equity of 29.53% beat Gilead Sciences's return on equity of 32.29%.

Exelixis has a consensus price target of $40.78, signalling downside risk potential of -3.8%. On the other hand Gilead Sciences has an analysts' consensus of $115.04 which suggests that it could grow by 7.14%. Given that Gilead Sciences has higher upside potential than Exelixis, analysts believe Gilead Sciences is more attractive than Exelixis.

Exelixis has a beta of 0.246, which suggesting that the stock is 75.352% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.263, suggesting its less volatile than the S&P 500 by 73.697%.

Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 2.89% to investors and pays a quarterly dividend of $0.79 per share. Exelixis pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Exelixis quarterly revenues are $555.4M, which are smaller than Gilead Sciences quarterly revenues of $6.7B. Exelixis's net income of $159.6M is lower than Gilead Sciences's net income of $1.3B. Notably, Exelixis's price-to-earnings ratio is 19.27x while Gilead Sciences's PE ratio is 22.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 5.38x versus 4.71x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Inovio Pharmaceuticals has a net margin of 28.74% compared to Exelixis's net margin of -30140.49%. Exelixis's return on equity of 29.53% beat Inovio Pharmaceuticals's return on equity of -125.47%.

Exelixis has a consensus price target of $40.78, signalling downside risk potential of -3.8%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $7.50 which suggests that it could grow by 280.71%. Given that Inovio Pharmaceuticals has higher upside potential than Exelixis, analysts believe Inovio Pharmaceuticals is more attractive than Exelixis.

Exelixis has a beta of 0.246, which suggesting that the stock is 75.352% less volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 1.401, suggesting its more volatile than the S&P 500 by 40.133%.

Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

Exelixis quarterly revenues are $555.4M, which are larger than Inovio Pharmaceuticals quarterly revenues of $65.3K. Exelixis's net income of $159.6M is higher than Inovio Pharmaceuticals's net income of -$19.7M. Notably, Exelixis's price-to-earnings ratio is 19.27x while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 5.38x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Lineage Cell Therapeutics has a net margin of 28.74% compared to Exelixis's net margin of -275.57%. Exelixis's return on equity of 29.53% beat Lineage Cell Therapeutics's return on equity of -22.68%.

Exelixis has a consensus price target of $40.78, signalling downside risk potential of -3.8%. On the other hand Lineage Cell Therapeutics has an analysts' consensus of $3.92 which suggests that it could grow by 666.32%. Given that Lineage Cell Therapeutics has higher upside potential than Exelixis, analysts believe Lineage Cell Therapeutics is more attractive than Exelixis.

Exelixis has a beta of 0.246, which suggesting that the stock is 75.352% less volatile than S&P 500. In comparison Lineage Cell Therapeutics has a beta of 1.414, suggesting its more volatile than the S&P 500 by 41.436%.

Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lineage Cell Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis pays -- of its earnings as a dividend. Lineage Cell Therapeutics pays out -- of its earnings as a dividend.

Exelixis quarterly revenues are $555.4M, which are larger than Lineage Cell Therapeutics quarterly revenues of $1.5M. Exelixis's net income of $159.6M is higher than Lineage Cell Therapeutics's net income of -$4.1M. Notably, Exelixis's price-to-earnings ratio is 19.27x while Lineage Cell Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 5.38x versus 11.28x for Lineage Cell Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vaxart has a net margin of 28.74% compared to Exelixis's net margin of -74.68%. Exelixis's return on equity of 29.53% beat Vaxart's return on equity of -94.14%.

Exelixis has a consensus price target of $40.78, signalling downside risk potential of -3.8%. On the other hand Vaxart has an analysts' consensus of $6.00 which suggests that it could grow by 1194.5%. Given that Vaxart has higher upside potential than Exelixis, analysts believe Vaxart is more attractive than Exelixis.

Exelixis has a beta of 0.246, which suggesting that the stock is 75.352% less volatile than S&P 500. In comparison Vaxart has a beta of 1.275, suggesting its more volatile than the S&P 500 by 27.53%.

Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vaxart offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis pays -- of its earnings as a dividend. Vaxart pays out -- of its earnings as a dividend.

Exelixis quarterly revenues are $555.4M, which are larger than Vaxart quarterly revenues of $20.9M. Exelixis's net income of $159.6M is higher than Vaxart's net income of -$15.6M. Notably, Exelixis's price-to-earnings ratio is 19.27x while Vaxart's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 5.38x versus 2.12x for Vaxart. Usually stocks with elevated PS ratios are considered overvalued.